Alzheimer's disease (AD) is still one of the most difficult diseases to diagnose. The diagnosis is based on a mental state assessment and complementary exams can be ordered, but are usually not enough to be conclusive. A new PET tracer has the possibility to change that. The first-and-only FDA-approved diagnostic PET tracer for estimation of beta-amyloid neuritic plaque density when evaluating for AD and other causes of cognitive decline. In Europe, it will also be available in the second-quarter of this year. This tracer can be seen as an evolution of 11C-PIB, as can be read here.
Official webpage: http://www.amyvid.com/Pages/index.aspx
Why early diagnosis is important? http://www.alz.org/research/science/earlier_alzheimers_diagnosis.asp